GSE202434 GSE202438 talazoparib 7 v 5 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE202434_GSE202438_talazoparib_7_v_5_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE202434_GSE202438_talazoparib_7_v_5_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE202434_GSE202438_talazoparib_7_v_5_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE202434_GSE202438_talazoparib_7_v_5_human_up.

Results found

Linked to

 

Label

Description

 

Gene

MIR4435-2 host gene

Gene

VPS9D1 antisense RNA 1

Gene

ZFHX3 antisense RNA 1

Gene

cancer susceptibility 8

Gene

uncharacterized LOC101929748

Gene

long intergenic non-protein coding RNA 1821

Gene

KCNQ1 antisense RNA 1

Gene

ribosomal protein SA pseudogene 14

Gene

long intergenic non-protein coding RNA 1470

Gene

ribosomal protein lateral stalk subunit P0 pseudogene 6


  • Gene

    VPS9D1 antisense RNA 1


  • Gene

    ZFHX3 antisense RNA 1


  • Gene

    cancer susceptibility 8


  • Gene

    uncharacterized LOC101929748


  • Gene

    long intergenic non-protein coding RNA 1821


  • Gene

    KCNQ1 antisense RNA 1


  • Gene

    ribosomal protein SA pseudogene 14


  • Gene

    long intergenic non-protein coding RNA 1470


  • Gene

    ribosomal protein lateral stalk subunit P0 pseudogene 6

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.